GlassScriptPhysician profile
Jacob Daniel Dunnam
NPI 1508525668
$4,482.27
in general payments reported to CMS, 2019-2025
23 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 97% of Critical Care Medicine (Registered Nurse) providers received nationally (typical 2025 total: $51.32).
See the full distribution for Critical Care Medicine (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $821 · 2023: $1,019 · 2024: $1,071 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,013.31 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $975.30 | 2022-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $750.74 | 2022-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Grifols USA, LLC | $286.79 | 2022-2023 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $255.87 | 2023-2025 | |
| Genzyme Corporation | $190.73 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $176.48 | 2024-2025 | Zerbaxa, Dificid, Recarbrio |
| United Therapeutics Corporation | $120.24 | 2022-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $100.19 | 2024-2025 | Dupixent |
| Viatris Specialty LLC | $92.58 | 2025 | Yupelri |
| Amgen INC. | $76.91 | 2024-2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $65.79 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $54.58 | 2024-2025 | Lumryz |
| Axsome Therapeutics, INC. | $54.24 | 2025 | Sunosi |
| Paratek Pharmaceuticals, INC. | $53.34 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.38 | 2022-2023 | |
| Verona Pharma, INC. | $43.19 | 2025 | Ohtuvayre |
| Chiesi USA, INC. | $42.65 | 2022-2025 | Cleviprex, Kengreal |
| Mallinckrodt Hospital Products INC. | $20.83 | 2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $18.07 | 2025 | Glassia |
| Mylan Specialty L.P. | $15.21 | 2024 | Yupelri |
| Alexion Pharmaceuticals, INC. | $13.59 | 2022 | |
| Glaxosmithkline, LLC. | $13.26 | 2024 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Dunnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.